oc) i by

Arg. Bras. Med. Vet. Zootec., v.75, n.5, p.771-786, 2023

Impact of adding different concentrations of IGF-I and insulin to the semen extender on bull sperm quality post-cryopreservation

[Impacto da adição de diferentes concentrações de IGF-I e insulina ao diluidor de sêmen sobre a qualidade espermática bovina após a criopreservação]

S.C.C. Pinto¹, F.A. Souza², R.P. Arruda¹, M.B.R. Alves¹, L. Batissaco¹, L.N. Garcia-Oliveros¹, M.S. Passarelli¹ L.C. Carneiro¹, E.C.C. Celeghini^{1*}

¹Centro de Biotecnologia em Reprodução Animal, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, Pirassununga, SP, Brasil ²Universidade Federal do Paraná, Curitiba, PR, Brasil

ABSTRACT

This study aimed to evaluate the addition of different concentrations of IGF-I and insulin to egg yolk-based extender to improve bovine semen cryopreservation. Two experiments were developed to evaluate the effects of the additives in two commercial extenders, Botubov[®] (Experiment 1) and Triladyl[®] (Experiment 2), both with the same design. Three ejaculates from four bulls (n = 12) were used. Each ejaculate was divided into seven equal fractions for dilution (60x10⁶ spermatozoa/mL) in the following treatments: CON: extender only; IGF100: IGF-I 100ng/mL; IGF200: IGF-I 200ng/mL; INS150: insulin 150µUI/mL; INS200: insulin 200µUI/mL; ASS1: IGF-I 100ng/mL + insulin 150µUI/mL; ASS2: IGF-I 200ng/mL + insulin 200µUI/mL. Semen was cryopreserved by an automated system. Post-thawed sperm were evaluated regarding motility by CASA (Computer-assisted sperm analysis), and membranes by fluorescent probes (H342, PI, FITC-PSA and JC-1). For Botubov[®] extender, INS150 was more efficient in preserving total and progressive motility, VCL, BCF, plasma and mitochondrial membranes. A similar response was seen when insulin was added to the Triladyl[®] extender, INS150 was more efficient in preserving sperm motility, plasma membrane integrity and mitochondrial potential. Thus, the addition of insulin 150µUI/mL, regardless of the composition of the extender, contributes to better preserving bovine sperm from the cryopreservation effects.

Keywords: Bull, Semen, Freezing, Botubov[®], Triladyl[®]

RESUMO

Este estudo teve o objetivo de avaliar a adição de diferentes concentrações de IGF-I e insulina a diluidores, à base de gema de ovo, para melhorar a criopreservação do sêmen bovino. Dois experimentos foram desenvolvidos para avaliar os efeitos dos aditivos em dois diluidores comerciais: Botubov[®] (Experimento 1) e Triladyl[®] (Experimento 2), ambos com o mesmo delineamento. Foram utilizados três ejaculados de quatro touros (n=12). Cada ejaculado foi dividido em sete frações para diluição ($60x10^{\circ}$ espermatozoides/mL), nos seguintes tratamentos: CON: somente diluidor; IGF100: 100ng/mL de IGF-I; IGF200: 200ng/mL de IGF-I; INS150: 150µUI/mL de insulina; INS200: 200µUI/mL de insulina; ASS1: 100ng/mL de IGF-I + 150µUI/mL de insulina; ASS2: 200ng/mL de IGF-I + 200µUI/mL de insulina. O sêmen foi criopreservado por sistema automatizado. Após a criopreservação, o sêmen foi avaliado quanto à motilidade espermática por CASA e quanto às membranas espermáticas (plasmática, acrossomal e mitocondrial) por sondas fluorescentes (H342, PI, FITC-PSA e JC-1). Para o diluidor Botubov[®], INS150 foi mais eficiente em preservar motilidades total e progressiva, VCL, BCF, integridade da membrana plasmática e potencial mitocondrial. Resposta semelhante foi observada quando a insulina foi adicionada ao diluidor Triladyl[®], INS150 foi mais eficiente na preservação da motilidade, integridade das membranas e potencial mitocondrial quando comparado aos demais grupos. Assim, a adição de 150µUI/mL de insulina aos diluidores, independentemente da composição, contribui para melhor criopreservação dos espermatozoides bovinos.

Palavras-chave: bovino, sêmen, congelação, Botubov[®], Triladyl[®]

^{*} Corresponding author: celeghin@usp.br

Submitted: January 9, 2023. Accepted: May 11, 2023

INTRODUCTION

Semen cryopreservation keeps sperm cells at cryogenic temperatures for a long term (Treulen et al., 2018) and allows the widespread use of artificial insemination in cattle (Grotter et al., 2019). However, the process of freezing and thawing the semen results in irreversible changes in sperm kinetics, membranes, and DNA integrity (Celeghini et al., 2008; Amidi et al., 2016). These changes directly reflect on the fertility of cryopreserved semen (Oliveira et al., 2014). Moreover, damage to cells during freezing may be related to osmotic stress, the formation of intracellular ice crystals, the production of reactive oxygen species or, simultaneously, the combination of all these factors (Grotter et al., 2019).

The fertilization capacity of cryopreserved sperm depends on the preservation of the integrity and functionality of the sperm structures, which are acquired by components of the extenders as ionic and non-ionic substances, responsible for maintaining osmolarity and buffering. Some components of the extenders are high molecular weight lipoproteins, present in egg yolk, crucial to avoid cold shock; intracellular cryoprotectants, such as glycerol; energy sources, represented by sugars like glucose and fructose; and other additives (Oliveira *et al.*, 2018).

To minimize some negative effects of semen cryopreservation, several additives are studied to guarantee better preservation of sperm cells, as reported by Pinto *et al.* (2020) in bovine, by Dalmazzo *et al.* (2018) in dogs, by Banday *et al.* (2017) in ovine and by Berkovitz *et al.* (2018) in humans. However, to the best of our knowledge, no additive was shown as minimizing the cryopreservation process by turning the post-thawed semen similar to *in natura* semen.

Bovine semen extenders supplemented with hormones such as IGF-I and insulin can improve post-thaw sperm metabolism and maximize the preservation of post-thaw sperm structures. Insulin is a protein composed of two chains (α and β , with 21 and 30 amino acids, respectively), which provides energy to sperm. This component is released into the seminal plasma, with the production of NADPH, influencing sperm capacitation and autocrine metabolism (Andó and Aquila, 2005). Autocrine metabolism is characterized by the releasing of insulin by sperm, which self-regulates glucose-6-phosphate dehydrogenase (G6PDH), an enzyme that limits the pentose phosphate pathway (PPP), essential for sperm to acquire motility and sperm capacitation, in addition to promoting fusion between gametes (Andó and Aquila, 2005; Aquila *et al.*, 2005). Previous studies adding insulin in the cryopreservation medium have shown better preservation of the plasma and acrosome membranes integrity, as well as the cellular metabolism (Van Tilburg *et al.*, 2008), decreased sperm DNA fragmentation (Shokri *et al.*, 2019) and increased sperm fertilizing capacity (Lampião and Plessis, 2008).

The insulin-like growth factor I (IGF-I) is a peptide similar to insulin and is a component of seminal plasma secreted by Leydig and Sertoli cells. IGF-I has a key role during spermatogenesis and steroidogenesis (Lee *et al.*, 2016). Also, it preserves sperm motility, as well as plasma and acrosome membranes integrity, as demonstrated for bovine (Henricks *et al.*, 1998), swine (Silva *et al.*, 2011), buffalo (Selvaraju *et al.*, 2016) and equine species with an increase in the pregnancy rate (Macpherson *et al.*, 2002).

Although insulin and IGF-I already have beneficial effects on sperm quality during cryopreservation, the best concentration of these additives and the impact of their association have not yet to be elucidated in cryopreserved bull sperm. Based on that, this study aimed to evaluate the addition of different concentrations of insulin and IGF-I in egg yolk-based extenders (Botubov[®] and Triladyl[®]) for bovine semen cryopreservation on sperm kinetics and plasma, acrosome and mitochondrial membranes, the benefit of the addition being expected even when the composition of the extenders is unknown.

MATERIAL AND METHODS

Four Nellore bulls with an average age of 55 ± 0.95 months and body weight of 921.25 ± 78.46 kg were used. The animals were kept in paddocks with pasture of *Brachiaria sp.* and mineral salt and water *ad libitum*. Concentrate was provided according to the nutritional requirements indicated for the category and age following the National

Research Council (NRC, 2016). The animals were weighed every 15 days. Before the beginning of the experiment, endo and ectoparasite control was performed. This study was conducted into two experiments, according to commercial egg-yolk-based extender used: Experiment 1: Botubov[®] and Experiment 2: Triladyl[®].

The experimental procedures were approved by the Ethics Committee on the Use of Animals (CEUA) of the School of Veterinary Medicine and Animal Science, the University of São Paulo-USP, Brazil (protocol CEUA number 2861160816).

In Experiment 1 (Addition of different concentrations of IGF-I and insulin to the Botubov[®] extender for cryopreservation of semen), three ejaculates from each four Nellore bulls were used (n = 12). The semen was collected by electroejaculation (Autojac, Neovet[®], Uberaba/SP/Brazil), in a 15-mL graduated tube. After collection, *in natura* semen was kept in a water bath at 37°C during evaluation. Each ejaculate was evaluated for volume, concentration, motility, vigor, and morphology.

Semen volume was determined by the graduated tube used during collection. The sperm concentration was determined in a Neubauer chamber, under optical microscopy at 400x magnification, after the previous dilution (1:100) in a buffered formaldehyde solution (4%). Sperm motility and vigor were evaluated with a semen drop between a slide and a coverslip, under optical microscopy (Nikon, Eclipse E200) at 100x magnification. Motility was estimated as a percentage of moving sperm and sperm vigor as a score from 1 to 5, according to the recommendations for bovine (Neves et al., 2013). Sperm morphology was performed under differential interference contrast (DIC)microscopy (Nikon, Eclipse 80i), between slide and coverslip at 1000x magnification. A total of 200 cells was counted and the results were expressed as a percentage, classified into major and minor defects according to Blom (1973).

The results of the analysis of the semen *in natura* were used for the choice of the ejaculate for the cryopreservation and for the dilution and preparation for the cryopreservation procedure.

Each ejaculate was divided into seven equal fractions, all diluted to a final concentration of 60×10^{6} Botubov[®] spermatozoa/mL in (Botupharma[®], Botucatu-SP) extender. Different concentrations of IGF-I (Sigma-Aldrich, I3760) and insulin (Sigma-Aldrich, I2643) were added. A total of seven treatment groups were performed as follows: BCON: only Botubov® extender (Control); BIGF100: Botubov[®] + 100 ng/mL of IGF-I; BIGF200: Botubov[®] + 200 ng/mL of IGF-I; BINS150: Botubov +150 µUI/mL of insulin; BINS200: Botubov + 200 µUI/mL of insulin; BASS1: Botubov +100 ng/mL of IGF-I + 150 µUI/mL of Insulin; BASS2: Botubov + 200 ng/mL of IGF-I + 200 µUI/mL of insulin.

The choice of IGF-I and insulin concentrations used in the experimental groups was supported by the basal concentrations of these hormones in the seminal plasma, as previously described (Henricks *et al.*, 1998; Andó and Aquila, 2005).

The semen diluted and supplemented with different hormonal concentrations were incubated for 10 minutes at 37°C for interaction between semen and treatment. Then, semen was packaged in French straws (0.25mL) labeled with the animal number, date, and treatment. Semen cryopreservation was performed in an automatic system (TK 3000 Plus®, Uberaba, MG, Brazil). For freezing, the semen was cooled at a rate of 0.25°C/minute until it reaches 5°C. Afterward, the straw holder was transferred to the thermal box containing liquid nitrogen until the temperature of -120°C, at a rate of -20°C/minute. Upon reaching this temperature, the straws were submerged in liquid nitrogen at -196°C. In the end, the straws were organized in racks and stored in cryogenic tanks according to each treatment and animal.

After thawing, two straws from each batch, bull and treatment were thawed in a water bath for 30 seconds at 37°C placed in microtubes, homogenized, and evaluated for motility and sperm membranes.

The characteristics of sperm motility were evaluated by Computer-Assisted Sperm Analysis – CASA (SCA[®], Sperm Class Analyzer; MICROPTIC, Barcelona, Spain). The setup was previously adjusted to evaluate bovine sperm. For the analysis, the samples were diluted in a concentration of 10×10^6 spermatozoa/mL in the TALP sperm medium. The diluted semen sample was placed in the Makler[®] chamber (Selfi-Medical Instruments, Haifa, Israel) for evaluation. The investigated characteristics were total motility (TM%), progressive motility (PM%), velocity average path (VAP, µm/s), velocity straight line (VSL, µm/s), velocity curved line (VCL, µm/s), wobble (WOB%), amplitude of lateral head displacement (ALH, µm), beat cross frequency (BCF, Hz), straightness (STR%) and linearity (LIN, %).

The evaluation of the plasma, acrosome and mitochondrial membranes followed the protocol described by Celeghini *et al.* (2008). An 150 μ L aliquot of the semen diluted in TALP sperm medium (Bavister and Lorraine, 1983) at 10x10⁶ concentration spermatozoa/mL was placed in a microtube and added 2 μ L of Hoechst 33342 (H342, 0.5 mg/mL, Molecular Probes, H1399), 2 μ L of propidium iodide (PI, 0.5 mg/mL in DPBS, Molecular Probes, P3566), 6 μ L of 5,5',6,6'-tetrachloro-1,1',3,3'-

tetraethylbenzimidazolcarbocyanine iodide (JC-1, 153 µM in DMSO, Molecular Probes, T3168) and 20 µL of fluorescein isothiocyanate-Pisum sativum agglutinin (FITC-PSA, 100 µg/mL in DPBS, Sigma, L0770). The samples were incubated for 8 minutes at 37°C. After incubation, a drop (4 µL) of sample was placed between the slide and coverslip (preheated at 37°C) and the reading was performed under epifluorescence microscopy (Nikon Epifluorescence Microscope, Model Eclipse 80i) in a triple filter (D/F/R, C58420) presenting the UV-2E/C (340-380nm excitation and 435-485nm emission), B-2E/C (465-495nm excitation and 515-555nm emission) and G-2E/C (540-525nm excitation and 605-655nm emission) at 1,000x magnification.

A total of 200 sperm cells were counted and classified into eight categories according to the fluorescence emitted by each probe, according to Celeghini *et al.* (2008). After counting, the percentages of the following cell populations were considered for this study: plasma membrane integrity (PI), acrosome integrity (AI), high mitochondrial membrane potential (HMP), and spermatozoa showing plasma and acrosome membranes integrity and high mitochondrial membrane potential (PIAIHP).

In Experiment 2 (Addition of different concentrations of IGF-I and insulin to the Triladyl[®] extender for cryopreservation of semen), three ejaculates from each four Nellore bulls were also used (n = 12). Semen collection was performed by electroejaculation (Autojac, Neovet[®], Uberaba/SP/ Brazil). After collection, *in natura* semen was kept in a water bath at 37°C during evaluation. Each ejaculate was evaluated for semen volume, sperm concentration, motility, vigor, and morphology, as described in Experiment 1, for the screening of the ejaculate to be used and for the cryopreservation procedure.

Each ejaculate was separated into seven equal fractions, all diluted to a final concentration of 60x10⁶ spermatozoa/mL in Triladyl[®] (prepared according to the manufacturer; Minitube[®]). Different concentrations of IGF-I (Sigma-Aldrich, I3760) and insulin (Sigma-Aldrich, I2643) were added with the same concentrations used in Experiment 1. A total of seven groups was performed as follows: TCON: only Triladyl[®] extender (Control); TIGF100: Triladyl[®] + 100ng/mL of IGF-I; TIGF200: Triladyl[®] + 200ng/mL of IGF-I; TINS150: Triladyl[®] + 150 μ UI/mL of insulin; TINS200: Triladyl[®] + 200µUI/mL of insulin; TASS1: Trilady1[®] + 100ng/mL IGF-I + 150µUI/mL insulin; TASS2: Triladyl[®] + 200 ng/mL of IGF-I + 200 µUI/mL of insulin.

The semen diluted and supplemented with different hormonal concentrations were incubated for 10 minutes at 37°C and packaged in French straws (0.25 mL) labeled with the animal number, date, and treatment. The semen cryopreservation process was the same as described in Experiment 1.

Two straws from each batch, bull, and treatment were thawed in a water bath (30 sec/37°C) placed in microtubes, homogenized, and evaluated for motility and sperm membranes.

For sperm motility, a total of 4 μ L of semen were dropped between slide and coverslip (pre-heated) for reading by phase-contrast microscopy (Nikon, Model Eclipse 200) at 100x magnification. The percentage of sperm motility was estimated according to the recommendation for bovine (Neves *et al.*, 2013) by an experienced technician. To evaluate plasma and acrosome membranes integrity and mitochondrial membrane potential was used the same protocol described in Experiment 1. A total of 200 cells were counted and classified into eight categories according to the fluorescence emitted by each probe, according to Celeghini *et al.* (2008) and after counting, the percentages of the followed cell populations were considered: plasma membrane integrity (PI), acrosome integrity (AI), high mitochondrial membrane potential (HMP), and spermatozoa showing plasma and acrosome membranes integrity and high mitochondrial membrane potential (PIAIHP).

Both experiments were performed in randomized blocks. Parametric variables were tested by

ANOVA and the means were compared by the Tukey test. All variables were tested for normality by Lilliefors. Variables that had subjective responses or did not show normal distribution after linear transformation were analyzed as nonparametric test, comparing the rankings using the Friedman test. The data were analyzed using the BioEstat 5.0 program. Statistical significance was defined as $P \le 0.05$.

RESULTS

The *in natura* sperm characteristics from each bull are presented in Table 1. In this table, are shown the mean and standard deviation from three ejaculates before semen cryopreservation.

Table 1. Mean and standard deviation of *in natura* sperm characteristics considering the three ejaculates of each bull before semen dilution to cryopreservation

Sharm abaractoristics	Bulls						
Sperm characteristics	1	2	3	4			
Motility (%)	75.0±5.0	78.33±2.88	71.66±2.88	73.33±2.88			
Vigor (1-5)	2.83±0.76	2.66±0.28	2.83±0.38	3±0			
Concentration ($x10^6$ sptz/mL)	215±80.46	470±268.37	169±56.712	570±247.84			
Major defects (%)	7.66 ± 0.57	6.66 ± 2.08	6.33±2.08	4±2.64			
Minor defects (%)	5.33±3.05	8.33±0.57	6.33±2.88	6±1.73			
PIAIHP (%)	79.66±5.03	85.33±2.08	77.66±9.71	78±8.66			

PIAIH= spermatozoa showing plasma and acrosome membranes integrity and high mitochondrial membrane potential

In experiment 1 using Botubov[®] extender, it was found that total motility was better preserved when 150μ UI/mL of insulin (BINS150) was added to the Botubov[®] extender compared to the control group (BCON) and the other concentrations the IGF-I and insulin (Fig. 1). On the other hand, the addition of 200μ UI/mL of insulin (BINS200) resulted in preservation of total motility similar to the control group (BCON), while all other treatments showed a decrease in total motility in relation to the BCON. The addition of 150 μ UI/mL of insulin (BINS150) also preserved progressive motility better than the other additives (BIGF100, BIGF200, BINS200, BASS1 and BASS2), but it was statistically similar to the BCON (Fig. 1).

In table 2, it is possible to observe that BINS150 group presented higher VCL and ALH than other groups. BCF was higher for BINS150 than for BIGF100, BIGF200 and BASS2, but it was similar to BCON. However, for VSL, VAP, LIN, STR and WOB characteristics, no effect of different concentrations of IGF-I and insulin using the Botubov[®] extender was observed.

Pinto et al.




Figure 1. Means and standard error of total and progressive motility of cryopreserved bovine semen using Botubov[®] extender added with different concentrations of IGF-1, insulin, and combinations.

^{a,bc} Different letters on the bars indicate statistically significant differences (P < 0.0001).

BIGF200: Botubov[®] + 200 ng/mL of IGF-I; BINS150: Botubov[®] +100 ng/mL of IGF-I; BIOS200: Botubov[®] + 200 μ UI/mL of insulin; BASS1: Botubov[®] +100 ng/mL of IGF-I + 150 μ UI/mL of Insulin; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of Insulin; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of Insulin; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of Insulin; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of INSULIN; BA

Table 2. Means (± standard error) of sperm motility characteristics of cryopreserved bovine semen using
Botubov [®] extender added with different concentrations of IGF-1, insulin, and combinations

Parâmetros	BCON	BIGF100	BIGF200	BINS150	BINS200	BASS1	BASS2	р
VCL (µm/s)	127.75±7.7 ^b	134.18±12.6 ^b	124.51±10.0 ^b	152.16±10.2ª	132.39±11.2 ^b	135.42±13.3 ^b	129±10.5 ^b	≤0.05
VSL (µm/s)	86.43±8.0	82.79±5.9	77.74±7.3	89.72±8.1	81.07±7.2	84.74±7.7	80.77±5.9	≥0.05
VAP (µm/s)	99.68±9.2	95.94±7.5	89.98±8.2	98.23±9.8	94.88±8.6	97.25±8.6	93.18±6.5	≥0.05
LIN (%)	62.42±2.07	62.51±3.26	62.39±3.26	62.73±2.83	61.22±2.48	63.10±2.49	63.50±1.92	≥0.05
STR (%)	84.49±2.96	85.83±1.26	83.21±4.20	85.74±3.42	82.71±2.61	84.92±3.15	84.37±3.19	≥0.05
WOB (%)	71.95±1.67	72.28±2.54	72.14±2.70	72.47±1.92	71.54±1.70	72.18±2.08	73.08±1.76	≥0.05
ALH (µm)	2.44±0.10 ^b	2.43±0.20 ^b	2.21±0.16 ^b	2.81±0.16 ^a	2.40±0.14 ^b	2.42±0.18 ^b	2.36±0.18 ^b	≤0.05
BCF (Hz)	22.89±0.97 ^{ab}	21.64±1.14 ^{bc}	21.01±1.17 ^c	23.60±1.14ª	22.46±0.87 ^{abc}	22.85±1.17 ^{ab}	22.0±1.15 ^{bc}	< 0.0001

^{a,bc} Different letters in the same line indicate statistically significant differences ($P \le 0.05$).

BCON (control): semen added only Botubov[®] extender; BIGF100: Botubov[®] + 100 ng/mL of IGF-I; BIGF200: Botubov[®] + 200 ng/mL of IGF-I; BINS150: Botubov[®] +150 μ UI/mL of insulin; BINS200: Botubov[®] + 200 μ UI/mL of insulin; BASS1: Botubov[®] +100 ng/mL of IGF-I + 150 μ UI /mL of Insulin; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of insulin. VCL = curvilinear velocity; VSL = progressive velocity; VAP = path velocity; LIN = linearity; STR = straightness; WOB = oscillation of the real path; ALH = amplitude of the lateral head; BCF = beat cross frequency

As shown in Figure 2, the addition of insulin (BINS150 and BINS200) was beneficial in preserving the integrity of the plasma membrane after cryopreservation; however, only the

concentration of 150 μ UI/mL of insulin statistically better than the BCON and the groups with other additives. On the other hand, for the potential of mitochondrial membrane (Fig. 2)

and acrosomal integrity (Table 3), no effect was noted of supplementation of IGF-I and insulin with the Botubov[®] extender. For the sperm population with the intact plasma membrane, intact acrosome, and high mitochondrial membrane potential (PIAIHP), the BINS150 group demonstrated a positive effect on the preservation of sperm membranes when compared to the other groups. Tables 4 and 5 show the individual responses of each bull to different semen additives. Table 4 presents the means and standard deviations of the sperm kinetics characteristics of three ejaculates from each bull, while in table 5 are the sperm membranes.




Figure 2. Means and standard error of plasma membrane integrity (PI), high mitochondrial membrane potential (HMP) and spermatozoa showing plasma and acrosome membranes integrity and high mitochondrial membrane potential (PIAIHP) of cryopreserved bovine semen using Botubov[®] extender added with different concentrations of IGF-1, insulin, and combinations

^{a,bc} Different letters on the bars indicate statistically significant differences ($P \le 0.05$). BCON (control): semen added only Botubov[®] extender; BIGF100: Botubov[®] + 100 ng/mL of IGF-I; BIGF200: Botubov[®] + 200 ng/mL of IGF-I; BINS150: Botubov[®] + 150 μ UI/mL of insulin; BINS200: Botubov[®] + 200 μ UI/mL of insulin; BASS1: Botubov[®] + 100 ng/mL of IGF-I + 150 μ UI /mL of Insulin; BASS2: Botubov[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of insulin.

Table 3. Means (\pm standard error) of acrosome integrity (AI) of cryopreserved bovine semen using Botubov[®] extender added with different concentrations of IGF-1, insulin, and combinations

Parameters	BCON	BIGF100	BIGF200	BINS150	BINS200	BASS1	BASS2
AI (%)	78.04±1.57	70.13±1.82	78.42±3.23	81.13±1.38	79.96±2.28	76.71±3.93	75.92±3.52

No statistically significant differences (P > 0.05).

BCON (control): semen added only Botubov[®] extender; BIGF100: Botubov[®] + 100 ng/mL of IGF-I; BIGF200: Botubov[®] + 200 ng/mL of IGF-I; BINS150: Botubov +150 μ UI/mL of insulin; BINS200: Botubov[®] + 200 μ UI/mL of insulin; BASS1: Botubov + 100 ng/mL of IGF-I + 150 μ UI/mL of Insulin; BASS2: Botubov + 200 ng/mL of IGF-I + 200 μ UI/mL of insulin.

Pinto et al.

msu	ini, and co	SM	TM	PM	VCL	VSL	VAP	LIN	STR	WOB	ALH	BCF
Bull	Treatment	SM (%)	1 M (%)	PM (%)	νCL (μm/s)	vSL (µm/s)	VAP (μm/s)	(%)	(%)	(%)	ALH (µm)	(Hz)
1		36.67±	47.77±	39.10±	128.43±	$\frac{(\mu m/s)}{101.47\pm}$	$\frac{(\mu m/s)}{114.20\pm}$	67.16±	88.77±	75.57±	$\frac{(\mu m)}{2.47\pm}$	24.67±
1	BCON	5.77	14.72	13.19	7.45	12.57	13.27	3.59	1.32	3.09	0.06	1.69
	BCON	33.33±	31.23±	22.93±	124.67±	82.57±	95.57±		85.87±	76.23±	2.30±	21.93±
	BIGF100	55.55± 5.77	31.23± 8.27	22.93± 9.40	124.07± 13.77	82.37± 19.31	93.37± 17.27	8.33	4.78	70.23± 5.47		21.95± 1.50
	BIGF100			9.40 26.27±							0.10	
	DICE200	30.00±	34.87±		127.67±	87.27±	98.53±	68.47±	88.63±	77.27±	$2.20\pm$	22.53±
	BIGF200	10.00	14.43	8.73	8.09	1.56	3.75	3.12	1.76	2.15	0.17	2.17
		56.67±	64.37±	47.50±	157.57±	114.77±	112.70±	70.40±	91.53±	75.97±	2.67±	25.43±
	BINS150	5.77	9.99	3.66	10.06	6.65	8.88	0.60	6.81	5.46	0.12	1.24
		$46.67 \pm$	$47.67 \pm$	$33.50 \pm$	136.53±	$85.47 \pm$	$106.43 \pm$	$62.57 \pm$	$85.60 \pm$	$73.07 \pm$	$2.47\pm$	$23.27 \pm$
	BINS200	11.55	20.75	11.52	6.39	7.06	15.88	3.07	2.86	1.96	0.12	0.23
		$35.00\pm$	$40.73 \pm$	$34.17\pm$	$140.73 \pm$	95.33±	$107.30 \pm$	$67.53\pm$	$88.73\pm$	$76.03\pm$	$2.43\pm$	23.27±
	BASS1	8.66	14.07	10.73	7.79	14.53	14.96	6.85	1.19	6.88	0.23	2.51
		31.67±	$27.10 \pm$	$21.60\pm$	132.97±	$88.97\pm$	101.43±	$66.73 \pm$	$87.40\pm$	$76.20 \pm$	$2.40\pm$	22.17±
	BASS2	2.89	4.06	5.36	4.81	12.44	9.34	7.06	4.29	4.50	0.00	1.19
2		45.00±	57.23±	$45.07 \pm$	148.73±	99.13±	116.97±	61.77±	$84.87\pm$	72.77±	2.67±	24.47±
	BCON	5.00	7.48	6.10	13.54	8.76	11.57	2.16	1.01	3.03	0.23	1.42
	20011	40.00±	37.53±	30.50±	168.47±	99.63±	117.30±		84.87±	69.80±	2.83±	24.70±
	BIGF100	17.32	23.83	21.06	11.42	6.18	3.87	5.37	2.72	4.69	0.25	1.75
	DIGI 100	33.33±	37.57±	29.00±	151.63±	92.13±	108.20±	60.77±	85.17±	71.40±	2.67±	22.97±
	BIGF200	55.55± 5.77	37.37± 11.64	29.00± 8.23	131.03± 4.49	92.13± 3.19	108.20± 3.21	3.21	2.33	71.40± 2.08	2.07± 0.21	1.10
	DIGF200						5.21 119.87±				0.21 3.10±	
	DB10150	58.33±	69.77±	51.83±	175.40±	103.80±			85.43±	71.63±		25.63±
	BINS150	7.64	17.15	10.45	8.26	3.48	4.57	6.35	2.80	5.02	0.17	0.81
		48.33±	56.53±	44.93±	162.10±	99.33±	117.20±	61.43±	84.73±	72.40±	2.70±	24.53±
	BINS200	2.89	6.79	9.32	6.48	6.31	2.76	5.97	3.35	4.12	0.20	0.55
		$38.33\pm$	$44.67\pm$	$36.10\pm$	$169.77\pm$	$100.73\pm$		$59.67 \pm$	$86.43\pm$	$68.83\pm$	$2.83\pm$	$25.97 \pm$
	BASS1	7.64	17.38	13.67	17.28	12.14	8.98	8.37	4.49	6.63	0.38	1.50
		$31.67\pm$	$39.10 \pm$	$31.43 \pm$	$152.73 \pm$	$92.77\pm$	106.13±	$61.30\pm$	$87.43 \pm$	$70.10 \pm$	$2.77\pm$	$25.03 \pm$
	BASS2	12.58	19.05	16.98	19.55	6.37	6.11	7.43	1.24	7.94	0.49	3.86
3		$40.00\pm$	$59.00\pm$	49.33±	111.93±	73.23±	82.90±	$63.60\pm$	88.33±	$72.00 \pm$	2.17±	21.50±
	BCON	10.00	19.63	18.92	10.72	2.51	2.60	1.51	0.31	1.67	0.12	0.72
		$41.67 \pm$	$48.73 \pm$	$42.73 \pm$	$108.77 \pm$	$74.57 \pm$	83.47±	$68.57 \pm$	$89.27 \pm$	$76.80\pm$	1.93±	$20.50 \pm$
	BIGF100	2.89	5.65	5.89	11.52	7.67	7.92	2.30	1.18	1.85	0.15	2.00
		$48.33\pm$	$57.50\pm$	51.77±	$108.67 \pm$	71.77±	81.60±	$66.30 \pm$	$88.33\pm$	$75.03 \pm$	$1.97\pm$	$20.77 \pm$
	BIGF200	10.41	3.42	6.86	7.17	5.92	6.51	1.51	0.59	1.55	0.06	0.21
		56.67±	73.67±	63.13±	126.27±	77.93±		67.23±	89.80±	74.87±	2.43±	22.27±
	BINS150	7.64	13.32	5.25	3.70	1.18	2.72	1.75	0.44	1.56	0.06	0.12
	DIGISO	51.67±	57.00±	51.33±	110.50±	73.47±	82.07±	66.40±	85.60±	74.17±	2.00±	21.27±
	BINS200	2.89	7.40	5.49	3.44	6.37	5.19	3.70	2.86	2.46	0.00	0.25
	DI (5200	50.00±	63.73±	55.87±	107.30±	72.03±		67.20±	2.00 88.90±	75.53±	1.93±	21.53±
	BASS1	10.00±	03.73± 3.03	2.42	107.30± 9.44	72.03± 5.59	6.64	07.20±	0.66	75.55± 0.93	1.93± 0.15	21.55± 0.50
	DA991	46.67±	56.60±	2.42 48.43±	9.44 101.77±	5.39 67.93±	0.04 77.20±	0.82 66.77±	0.00 87.83±	0.93 76.07±	0.15 1.87±	0.50 21.30±
	DASSO					10.24						
4	BASS2	7.64	5.64	5.42	16.18		10.39	2.11	1.89	2.00	0.21	1.47
4	DCON	41.67±	46.30±	39.73±	121.93±	71.92±	81.33±	57.17±	84.23±	67.47±	$2.47\pm$	20.93±
	BCON	18.93	32.54	29.44	7.58	16.62	10.40	10.00	7.22	6.31	0.21	1.21
		41.67±	$38.23\pm$	$29.83 \pm$	$134.83 \pm$	$74.40 \pm$	87.43±	$56.53 \pm$	$85.20\pm$	$66.30\pm$	$2.67 \pm$	$19.43 \pm$
	BIGF100	22.55	27.45	2132	33.76	6.66	9.42	8.42	1.81	9.04	0.81	2.72
		23.33±	$22.00\pm$	17.53±	$110.10\pm$	$59.80\pm$	71.60±	$54.03 \pm$	$82.00\pm$		$2.00\pm$	$17.80 \pm$
	BIGF200	5.77	24.39	18.28	3.12	19.84	16.91	16.95	9.89	13.91	0.26	3.12
		$50.00\pm$	$54.93 \pm$	$45.63\pm$	$149.43 \pm$	$84.93\pm$	$82.07\pm$	$55.30\pm$	$81.90\pm$	$67.40\pm$	$3.07\pm$	$21.07 \pm$
	BINS150	17.32	25.28	21.08	20.27	5.16	15.77	6.63	5.38	3.91	0.55	1.22
		41.67±	43.50±		120.43±	66.03±	$80.50\pm$	$54.47 \pm$	81.30±	66.53±	2.43±	$20.77 \pm$
	BINS200	18.93	29.70	24.16	6.15	16.11	13.91	10.86	6.12	8.41	0.21	0.92
	21.5200	26.67±	29.67±		123.90±	70.90±	84.43±		83.53±		2.50±	20.63±
	BASS1	5.77	20.13	15.68	4.01	12.68	8.62	12.58	6.91	8.84	0.35	0.95
	DUDOI	26.67±	20.13 30.80±		4.01 128.53±	73.43±	87.97±		83.90±		2.43±	19.50±
	BASS2				$128.35\pm$ 30.20							
SM -		5.77	13.47	13.15	= prograssiv	1.60	7.08	13.21	7.88	9.70	0.67	0.72

Table 4. Means and standard deviation from three ejaculates of each bull of sperm motility characteristics of cryopreserved bovine semen using Botubov[®] extender added with different concentrations of IGF-1, insulin, and combinations

SM = subjective motility; TM = total motility; PM = progressive motility; VCL = curvilinear velocity; VSL = progressive velocity; VAP = path velocity; LIN = linearity; STR = straightness; WOB = oscillation of the real path; ALH = amplitude lateral of the head; BCF = beat cross frequency. BCON (control): semen added only Botubov[®] extender; BIGF100: Botubov[®] + 100ng/mL of IGF-I; BIGF200: Botubov[®] + 200ng/mL of IGF-I; BINS150: Botubov[®] + 150µUI/mL of insulin; BINS200: Botubov[®] + 200µUI/mL of insulin; BASS1: Botubov[®] + 100ng/mL of IGF-I + 150µUI/mL of Insulin; BASS2: Botubov[®] + 200ng/mL of IGF-I + 200µUI/mL of insulin; BASS1: Botubov[®] + 200µUI/mL of insulin; BASS2: Botubov[®] + 200µUI/mL of insulin.

Impact of adding...

Table 5. Means and standard deviation from three ejaculates of each bull of plasma membrane integrity (PI), intact acrosome (IA), high mitochondrial membrane potential (HMP) and spermatozoa showing plasma and acrosome membranes integrity and high mitochondrial membrane potential (PIAIHP) of cryopreserved bovine semen using Botubov[®] extender added with different concentrations of IGF-1, insulin, and combinations

Bull	Treatment	PI (%)	IA (%)	HMP (%)	PIAIHP (%)
1	BCON	45.00±23.94	78.33±18.99	44.17±22.75	32.83±13.32
	BIGF100	31.83±14.22	66.00±16.04	22.33±16.65	21.67±17.18
	BIGF200	29.33±10.42	76.00±19.98	25.83±9.78	20.50±3.77
	BINS150	59.00±11.00	80.17±13.53	52.33±13.16	56.33±12.50
	BINS200	41.33±18.66	73.67±21.33	39.83±17.96	39.83±17.96
	BASS1	27.50 ± 6.08	65.83±15.00	41.17±24.57	26.17±5.20
	BASS2	17.83 ± 5.80	74.17±28.29	41.17±40.90	15.83±3.25
2	BCON	45.67±12.66	80.33±6.21	52.00±19.92	45.00±13.48
	BIGF100	39.50±17.39	74.83±9.22	38.50±17.76	37.83±16.60
	BIGF200	30.83±12.39	75.83±8.08	31.17±12.34	29.33±11.24
	BINS150	65.50±12.13	82.17±7.52	55.50±17.30	61.50±15.88
	BINS200	$50.00{\pm}10.58$	84.00±6.14	47.83±11.41	54.00 ± 17.50
	BASS1	32.50 ± 15.80	78.50±19.22	41.83±6.01	31.17±15.63
	BASS2	32.83±8.69	71.17±3.01	33.67±12.35	31.67±9.83
3	BCON	32.67±7.37	80.00±4.36	32.33±15.12	30.83 ± 7.08
	BIGF100	31.83±3.18	70.33±24.95	28.00±4.09	26.50 ± 4.58
	BIGF200	41.50±6.50	88.00±2.60	45.67±4.65	39.17±7.94
	BINS150	48.33±9.45	84.33±5.03	41.00±11.27	46.33±8.50
	BINS200	40.33±5.35	79.67±3.25	37.67±5.11	35.67±0.29
	BASS1	43.83±16.43	84.67±2.57	41.67 ± 15.82	40.67±17.47
	BASS2	38.83±3.62	86.33±4.19	38.83±4.25	35.83±1.89
4	BCON	27.67±14.98	73.50±5.27	30.17±18.82	27.00±16.09
	BIGF100	22.83±12.09	63.33±14.05	28.50±4.77	21.00±11.32
	BIGF200	24.17±17.62	73.83±9.45	27.17±16.65	21.83±17.82
	BINS150	46.50±15.88	77.83±5.20	39.67±17.06	45.00±16.53
	BINS200	34.17±15.73	82.50±12.32	33.17±16.44	29.50±17.76
	BASS1	30.83±17.25	77.83±11.62	29.67±17.92	23.50±14.41
	BASS2	24.33±8.02	71.17±8.25	30.17±13.48	21.50±9.26

BCON (control): semen added only Botubov[®] extender; BIGF100: Botubov[®] + 100ng/mL of IGF-I; BIGF200: Botubov[®] + 200 ng/mL of IGF-I; BINS150: Botubov[®] +150 μ UI/mL of insulin; BINS200: Botubov[®] + 200 μ UI/mL of insulin; BASS1: Botubov[®] +100 ng/mL of IGF-I + 150 μ UI /mL of Insulin; BASS2: Botubov[®] + 200ng/mL of IGF-I + 200 μ UI/mL of insulin.

In experiment 2 using Tryladyl[®] extender, the addition of insulin regardless of concentration (150 and 200μ UI/mL), to the Triladyl[®] extender for cryopreservation of semen improved the

preservation of sperm motility when compared to the other groups (Fig. 3).

According to the results, the highest percentages of plasma membrane integrity (Fig. 4) and high

mitochondrial membrane potential (Fig. 5) for post-cryopreservation semen were obtained when 150 μ UI/mL of insulin (TINS150) was added to the Triladyl[®] extender; however, these values did not differ from the TCON group. The same result was observed for the percentage of PIAIHP cells (Fig. 6). On the other hand, acrosome integrity was not affected by the addition of hormones (Table 6).

In the table 7 are shown the means and standard deviations of the sperm characteristics of three ejaculates from each bull after cryopreservation with the Triladyl[®] extender with the different additives, allowing the individual response of each bull to be evaluated.




Figure 3. Means and standard error of sperm motility of cryopreserved bovine semen using Triladyl[®] extender added with different concentrations of IGF-1, insulin, and combinations.

^{a,bc} Different letters on the bars indicate statistically significant differences ($P \le 0.0001$). TCON (Control): semen added only Triladyl[®]; TIGF100: Triladyl[®] + 100 ng/mL of IGF-I; TIGF200: Triladyl[®] + 200 ng/mL of IGF-I; TINS150: Triladyl[®] + 150 μ UI/mL of insulin; TINS200: Triladyl[®] + 200 μ UI/mL of insulin; TASS1: Triladyl[®] + 100 ng/mL IGF-I + 150 μ UI/mL insulin; TASS2: Triladyl[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of insulin.




Figure 4. Means and standard error of plasma membrane integrity (PI) of cryopreserved bovine semen using Triladyl[®] extender added with different concentrations of IGF-1, insulin, and combinations.

^{a,bc} Different letters on the bars indicate statistically significant differences (P ≤ 0.05). TCON (Control): semen added only Triladyl[®]; TIGF100: Triladyl[®] + 100 ng/mL of IGF-I; TIGF200: Triladyl[®] + 200 ng/mL of IGF-I; TINS150: Triladyl[®] + 150 µUI/mL of insulin; TINS200: Triladyl[®] + 200 µUI/mL of insulin; TASS1: Triladyl[®] + 100 ng/mL IGF-I + 150 µUI/mL insulin; TASS2: Triladyl[®] + 200 ng/mL of IGF-I + 200 µUI/mL of insulin.

Impact of adding...




Figure 5. Means and standard error of high mitochondrial membrane potential (HMP) of cryopreserved bovine semen using Triladyl[®] extender added with different concentrations of IGF-1, insulin, and combinations. ^{a,bc} Different letters on the bars indicate statistically significant differences ($P \le 0.05$). TCON (Control): semen added only Triladyl[®]; TIGF100: Triladyl[®] + 100 ng/mL of IGF-I; TIGF200: Triladyl[®] + 200 ng/mL of IGF-I; TINS150: Triladyl[®] + 150 µUI/mL of insulin; TINS200: Triladyl[®] + 200 µUI/mL of insulin; TASS1: Triladyl[®] + 100 ng/mL IGF-I + 150 µUI/mL insulin; TASS2: Triladyl[®] + 200 ng/mL of IGF-I + 200 µUI/mL of insulin.




Figure 6. Means and standard error of percentage of spermatozoa showing plasma and acrosome membranes integrity and high mitochondrial membrane potential (PIAIHP) of cryopreserved bovine semen using Triladyl[®] extender added with different concentrations of IGF-1, insulin, and combinations^{a,bc} Different letters on the bars indicate statistically significant differences ($P \le 0.0001$).

TCON (Control): semen added only Triladyl[®]; TIGF100: Triladyl[®] + 100 ng/mL of IGF-I; TIGF200: Triladyl[®] + 200 ng/mL of IGF-I; TINS150: Triladyl[®] + 150 μ UI/mL of insulin; TINS200: Triladyl[®] + 200 μ UI/mL of insulin; TASS1: Triladyl[®] + 100 ng/mL IGF-I + 150 μ UI/mL insulin; TASS2: Triladyl[®] + 200 ng/mL of IGF-I + 200 μ UI/mL of insulin.

Pinto	et	al.
-------	----	-----

Table 6. Means (\pm standard error) of acrosome integrity (AI) of cryopreserved bovine semen using Triladyl[®] extender added with different concentrations of IGF-1, insulin, and combination

D				,	,,		CDD 4 T
Parameters	TCON	TIGF100	11GF200	TINS150	TINS200	TASS1	TASS2
AI (%)	81.70±3.21	81.58±1.82	80.45±3.50	87.47±3.89	82.29±2.07	83.91±3.71	83.62±2.33

No statistically significant differences (P > 0.05). TCON (Control): semen added only Triladyl[®]; TIGF100: Triladyl[®] + 100 ng/mL of IGF-I; TIGF200: Triladyl[®] + 200 ng/mL of IGF-I; TINS150: Triladyl[®] + 150 µUI/mL of insulin; TINS200: Triladyl[®] + 200 µUI/mL of insulin; TASS1: Triladyl[®] + 100 ng/mL IGF-I + 150 µUI/mL insulin; TASS2: Triladyl[®] + 200 ng/mL of IGF-I + 200 µUI/mL of insulin.

Table 7. Means and standard deviation from three ejaculates of each bull of subjective motility (SM), plasma membrane integrity (PI), intact acrosome (IA), high mitochondrial membrane potential (HMP), and spermatozoa showing plasma and acrosome membranes integrity and high mitochondrial membrane potential (PIAIHP) of cryopreserved bovine semen using Triladyl[®] extender added with different concentrations of IGF-1, insulin, and combinations

Bull	Treatment	SM (%)	PI (%)	IA (%)	HMP (%)	PIAIHP (%)
1	TCON	46.67±5.77	42.50±7.47	76.33±14.75	80.17±9.67	40.83±9.00
	TIGF100	48.33 ± 5.77	37.67±9.57	77.17±13.14	81.67±9.50	37.67±9.57
	TIGF200	40.00 ± 5.00	23.50±10.00	78.50±18.03	67.33±14.07	23.17±9.75
	TINS150	65.00 ± 0.00	48.17±12.85	87.00 ± 9.84	85.17 ± 5.80	48.17±12.85
	TINS200	58.33±7.64	50.83 ± 6.83	78.83 ± 5.25	80.17 ± 4.19	48.33±7.11
	TASS1	45.00 ± 0.00	31.50±4.27	84.33±14.01	75.17±10.30	31.33±4.25
	TASS2	38.33±7.64	34.00±15.52	84.50±12.62	62.83±14.92	33.50±15.31
2	TCON	40.00 ± 0.00	54.50 ± 10.40	85.67±9.07	66.83±19.21	50.00±10.04
	TIGF100	53.33±5.77	40.83±4.91	80.83±11.45	70.50±16.50	40.50±5.22
	TIGF200	45.00 ± 0.00	34.00±9.99	78.00±15.22	67.83±13.33	33.00±9.73
	TINS150	60.00 ± 5.00	55.00 ± 5.77	95.83±4.37	86.33±0.58	54.50 ± 4.92
	TINS200	55.00 ± 5.00	46.33±6.66	85.00±8.67	80.17±8.28	45.67±7.29
	TASS1	43.33±14.43	32.33±10.56	85.33±6.90	79.00 ± 4.44	32.00±9.99
	TASS2	36.67±11.55	49.50±20.66	77.67±20.89	62.67±13.58	36.67±8.22
3	TCON	26.67±5.77	18.83±10.25	88.67±9.29	64.50±43.75	16.50±12.58
	TIGF100	35.00 ± 8.66	21.67±17.16	86.00±3.12	78.00 ± 18.21	21.00±16.09
	TIGF200	30.00 ± 5.00	23.83±15.25	90.67±5.48	73.33±27.43	23.50±15.26
	TINS150	48.33±2.89	27.17±2.02	89.83±6.79	77.33±26.84	27.00±2.00
	TINS200	40.00 ± 0.00	19.33±7.25	86.67±9.39	64.83 ± 40.18	17.50±6.06
	TASS1	33.33±2.89	15.50 ± 10.04	92.00±8.05	75.67±18.76	14.83±9.65
	TASS2	26.67±7.64	15.83±7.65	83.33±13.32	58.33±24.10	15.50±7.37
4	TCON	25.00 ± 5.00	19.00±9.34	76.17±14.77	59.83±36.30	19.00±9.34
	TIGF100	23.33±15.28	6.67±4.25	82.33±13.29	42.00±35.38	6.67±4.25
	TIGF200	25.00±13.23	11.67±10.75	74.67±21.68	39.83±33.14	$10.8310.05 \pm$
	TINS150	40.00±15.00	22.00 ± 8.72	77.17±14.34	57.83±22.68	21.67±8.50
	TINS200	33.33±20.21	13.50±10.64	78.67±14.22	63.50±38.67	13.17±10.91
	TASS1	20.00±0.00	8.50 ± 8.79	74.00±16.82	29.50±30.63	8.17±8.69
	TASS2	25.00±8.66	9.00±0.87	89.00±19.05	28.83±23.96	8.83±1.15

TCON (Control): semen added only Triladyl[®]; TIGF100: Triladyl[®] + 100ng/mL of IGF-I; TIGF200: Triladyl[®] + 200ng/mL of IGF-I; TINS150: Triladyl[®] + 150 μ UI/mL of insulin; TINS200: Triladyl[®] + 200 μ UI/mL of insulin; TASS1: Triladyl[®] + 100ng/mL IGF-I + 150 μ UI/mL insulin; TASS2: Triladyl[®] + 200ng/mL of IGF-I + 200 μ UI/mL of insulin.

DISCUSSION

Several factors during sperm cryopreservation process affect the sperm performance after thawing, which includes the *in natura* sperm quality, the freeze/thaw method, and the extenders and cryoprotectants used (Grotter *et* *al.*, 2019). The process of semen freezing induces physical and chemical stress, which causes damage to sperm plasma membrane, mitochondria, acrosome, motility, and morphology. All of these result in a decrease in the sperm fertilization ability (Shokri *et al.*, 2019). In this study, IGF-I and insulin, at

different concentrations, were added to two extenders egg yolk-based, to improve the preservation of function and structure of bovine sperm from cryopreservation damage, and this benefit is expected even when the definition of extenders composition is unknown.

The first experiment was carried out with a commercial extender (Botubov[®]), which has in its composition sugars, antioxidants, amino acids, egg yolk, glycerol, and water (Botupharma[®], Botucatu-SP). In the second experiment, the interaction of the additives in another commercial semen extender (Triladyl[®]) was tested; this one with sugars, TRIS (Hydroxymethyl), citric acid, buffers, antibiotics, egg yolk, glycerol, and water (Minitube[®]) in its composition. Although both extenders are based on egg yolk and have similar components, the exact composition of each one is unknown, protected by trade secrets. Thus, different interactions could occur that could show different benefits of the additives in favor of one of them. However, similar results were observed regarding the characteristics that were evaluated. The groups that received insulin at a concentration of 150 µUI/mL, in both experiments, presented better preservation of the sperm cells during freezing, reflecting in a higher percentage of sperm motility and intact cells components after thawing.

The improvement in the preservation of sperm motility with the addition of insulin, found in both experiments, can be explained by its performance, already well defined in the previous literature. Briefly, sperm motility is a process dependent on the production of ATP and the glycolytic enzymes present in the fibrous sheath of the flagella are one of the main energy suppliers. In addition, the mitochondria located in the intermediate piece are also energy suppliers by oxidative phosphorylation (Takei et al., 2014). Energy is important for motility maintenance. sperm capacitation and subsequently oocyte fertilization, as the energy is produced by the metabolism of external substrates (Ding et al., 2015). Small molecules such as monosaccharides easily cross the sperm plasma membrane bilayer, the other molecules receive support from membrane proteins that can actively or passively transport glucose (Ding et al., 2015). The presence of insulin is crucial for the glucose movement across the plasma membrane; however, when semen is diluted for cryopreservation, there is a decrease in the concentration of insulin present in the seminal plasma, so it is believed that its addition to the extender in the present study enabled the glucose to move across membranes, subsequently producing more ATP, which is essential for sperm motility.

Other studies corroborate the present, such as in humans, in which the cryopreserved semen with different concentrations of insulin (10, 100, 500 and 1000 ng/mL) increased the sperm motility percentage (Shokri et al., 2019). In other study, human semen supplemented with insulin (10 µmol) and leptin has shown a prolonged preservation of sperm motility and acrosomal reaction, thus increasing the oocyte's fertilization capacity (Lampião and Plessis, 2008). Men with insulin deficiency production had lower percentages of sperm motility and increased sperm defects, mainly from the acrosome region (Baccetti et al., 2002). The action of insulin on sperm kinetics is due to this affinity of 100 to 1,000 times for the heterologous receptors present in the sperm membranes, in this case, those of IGF-I, thus favoring sperm motility for greater glucose uptake (Clemmons et al., 1992).

In the present study, it was observed a higher percentage of cells with the intact plasma membrane. intact acrosome, and high mitochondrial membrane potential (PIAIHP) when insulin (150 µUI/mL) was added to both extenders. Such responses to the insulin action can be assured, since the plasma membrane, acrosomal and metabolism are cytological targets (Souza et al., 2012). During semen cryopreservation, between 15° to 5° C, mostly membranes alterations occur, such as rupture and loss in the phospholipid arrangements. In this interval, the plasma membrane changes its state from liquid to gel, decreasing the motility and increasing its permeability. Integral proteins, present in the plasma membrane, also suffer modulation during cryopreservation (Watson, 2000). Thus, it is believed that insulin binds to the sperm membrane receptors, which allows more protection during the cryopreservation process.

Reinforcing the results presented in this study, according to Aquila *et al.* (2005), the sperm mobilizes insulin from its granules at the time of

hyperactivation, and this process activates a better source of energy to the sperm cell, which, in turn, destabilizes the components that maintain the integrity of the plasma and acrosomal membranes before acrosomal reaction. This statement was verified in the present study, as the treatments that used insulin, especially in the concentration of 150 μ UI/mL, had the highest percentage of intact cells (PIAIHP). The same was observed when membranes integrity was separately evaluated for both extenders tested.

Van Tilburg *et al.* (2008) found a significant effect of insulin on acrosome integrity. They reported that the higher the concentration of insulin was added to the freezing extender the greater is the sperm with intact acrosome, still, insulin does not induce the acrosome reaction but preserves the integrity of the acrosome, attributing the action of this by inhibiting the binding of cAMP to cAMP-dependent protein kinase and activating the phosphatidylinositol 3-, 4-bisphosphate and phosphatidyl -inositol 3,4,5triphosphate, mechanisms responsible for capacitation and acrosome reaction. However, this effect was not found in the present study.

In relation to IGF-I, no significant effect was reported of its action on the different extenders, the same was observed by Costa et al. (2020) in a study with bovine cryopreserved semen. They added 150 ng/mL of IGF-I to the extender and no effects were also observed. Differently, Henricks et al. (1998), Pan et al. (2015), Sang-Min et al. (2014), Serveraju et al. (2009), Maskarevich et al. (2014) and Padilha et al. (2012), in cattle, dogs, buffalo ram, goats and ovine, respectively, found an improvement in the sperm quality when extenders were supplemented with different concentrations of IGF-I. According to Kumar et al. (2019), in buffaloes, IGF-I increased the concentration of intracellular calcium, resulting in better progressive sperm motility. However, this was not noticed in the current study and could be explained by the difference in membranes composition, by the sensitivity to cryopreservation between species and by the concentration, IGF-I added in the cryopreservation extenders.

The addition of IGF-I and insulin combined did not improve sperm quality after thawing in both Triladyl[®] and Botubov[®] extenders. It was expected that the association of these hormones would guarantee better cell preservation, as IGF-I acted on sperm motility and linear speed, through the connection with receptors present in sperm, and that insulin acted on metabolism (Souza *et al.*, 2012). The associated groups showed a lower percentage of sperm motility and a lower number of intact cells. The concentration used in these associations likely provided a cytotoxic effect to sperm, decreasing sperm motility, membrane integrity and providing greater damage to cells.

CONCLUSION

In conclusion, the addition of 150 μ UI/mL of insulin to egg yolk-based extenders (Botubov[®] and Triladyl[®]) improves the preservation of sperm motility, plasma membrane integrity and high mitochondrial membrane potential in cryopreserved bovine semen, regardless of the extender composition.

FINANCING STATEMENT

This research had financial support from the São Paulo Research Support Foundation (FAPESP 2016/05395-1), from the National Council for Scientific and Technological Development (CNPq 154967-2016-5 and 306291/2017-7) and Alta Genetics- Brazil.

ACKNOWLEDGMENTS

The authors would thank João Carlos Pinto de Campos, Márcio Donizete De Carli, and José Maria Bernardi for assistance with the animals of the Center of Biotechnology in Animal Reproduction. The authors are also grateful to all participants directly and indirectly, without them research would be impossible.

REFERENCES

AMIDI, F.; PAZHOHAN, A.; SHABANI, N.M. *et al.* The role of antioxidants in sperm freezing: a review. *Cell Tissue Bank*, v.17, p.745-756, 2016.

ANDÓ, S.; AQUILA, S. Arguments raised by the recent discovery that insulin and leptin are expressed in and secreted by human ejaculated spermatozoa. *Mol. Cell. Endocrinol.*, v.245, p.1-6, 2005. AQUILA, S.; GENTILE, M.; MIDDEA, E. *et al.* Autocrine regulation of insulin secretion in human ejaculated spermatozoa. *Endocrinology*, v.146, p.552-557, 2005.

BACCETTI, B.; LA MARCA, A.; PIOMBONI, P. *et al.* Insulin-dependent diabetes in men is associated with hypothalamo-pituitary derangement and with impairment in semen quality. *Hum. Reprod.*, v.17, p.2673-2677, 2002.

BANDAY, M.N.; LONE; F.A.; RASSOL, F. *et al.* Use of antioxidants reduce lipid peroxidation and improve quality of crossbred ram sperm during its cryopreservation. *Cryobiology*, v.74, p.25-30, 2017.

BAVISTER, D.; LORRAINE, M. Development of preimplantation in a defined embryo of the Golden hamster in a defined culture medium. *Biol. Reprod.*, v.28, p.235-247, 1983.

BERKOVITZ, A.; ALLOUCHE-FITOUSSI, D.; IZAHAKVOC, D. *et al.* Cryopreservation of human sperm in the presence of Zinc²⁺ increases the motility rate. *J. Obstet. Gynecol. Investig.*, v.1, p.1-7, 2018.

BLOM, E. The ultrastructure of some characteristic sperm defects and a proposal for a new classification of the bulls spermiogram. *Nord. Vet. Med.*, v.25, p.383-391, 1973.

CELEGHINI, E.C.C.; ARRUDA, R.P.; ANDRADE, A.F.C. *et al.* Effects that bovine sperm cryopreservation using two different extenders has on sperm membranes and chromatin. *Anim. Reprod. Sci.*, v.104, p.119-131, 2008.

CLEMMONS, D.R.; DEHOFF, M.L.; BUSBY, W.Y. *et al.* Competition for binding to insulinlike growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs. *Endocrinology*, v.131, p.890-895, 1992.

COSTA, O.J.S.; ALMEIDA. D.S.; PINTO. S.C.C. *et al.* Insulina e IGF-1 no meio extensor de criopreservação seminal bovina. *Arq. Bras. Med. Vet. Zootec.*, v.72, p.664-672, 2020.

DALMAZZO, J.D.A.; LOSANO, C.C.; ROCHA, R.H. *et al.* Effects of soy lecithin extender on dog sperm cryopreservation. *Anim. Biotech.*, v.29, p.174-182, 2018. DING, G.L.; LIU, M.; PAN, J.X.; GUO, M.X. *et al.* The effects of diabetes on male fertility and epigenetic regulation during spermatogenesis. *Asian J. Androl.*, v.17, p.948-953, 2015.

GROTTER, L.G.; CATTANEO, L.; MARINI, P.E. *et al.* Recent advances in bovine sperm cryopreservation techniques with a focus on sperm post-thaw quality optimization. *Reprod. Domest. Anim.*, v.54, p.655-665, 2019.

HENRICKS, D.M.; KOUBA, A.J.K.; LACKEY, B.R. *et al.* Identification of insulin-like growth factor 1 in bovine seminal plasma and its receptor on spermatozoa: influence on sperm motility. *Biol. Reprod.*, v.59, p.330-337, 1998.

KUMAR, P.; DALAL, P.; BHARDWAJ, S. *et al.* Serum and seminal plasma IGF-1 associations with semen variables and effect of IGF-1 supplementation on semen freezing capacity in buffalo bulls. *Anim. Reprod. Sci.*, v.204, p.101-110, 2019.

LAMPIÃO, F.; PLESSIS, S.S.D. Insulin and leptin enhance human sperm motility, acrosome reaction and nitric oxide production. *Asian J. Androl.*, v.10, p.799-807, 2008.

LEE, H.S.; PARK, Y.S.; LEE, J.S.; SEO, J.T. Serum and seminal plasma insulin-like growth factor-1 in male infertility. *Clin. Exp. Reprod. Med.*, v.43, p.97-101, 2016.

MACPHERSON, M.L.; SIMMEN, R.C.M.; SIMMEN, F.A. *et. al.* Insulin-like growth factor-I and insulin-like growth fator binding protein-2 and -5 equine seminal plasma: Association with sperm characteristics and fertility. *Biol. Reprod.*, v.67, p.648-654, 2002.

MAKAREVICH, A.V.; SPALEKOVA, E.; OLEXIKOVA, L. *et al.* Effect of insulin-like growth factor I on functional parameters of ram cooled-stored spermatozoa. *Zygote*, v.22, p.305–313, 2014.

NEVES, J.P.; HENRY, M.R.J.M.; JOBIM, M.I.M. *Manual para exame andrológico e avaliação de sêmen animal.* 3.ed. Belo Horizonte: CBRA, 2013. 104p.

NRC, National Research Council. *Nutrient requirements of beef cattle: eighth revised edition*. National Academies of Sciences, Engineering, and Medicine, 2016. 494 p. OLIVEIRA, B.M.; ARRUDA, R.P.; THOMÉ, H.E. *et al.* Fertility and uterine hemodynamic in cows after artificial insemination with semen assessed by fluorescent probes. *Theriogenology*, v.82, p.767-772, 2014.

OLIVEIRA, M.K.B.; ZANDONAIDE, J.P.B.; SEVERO, N.C. *et al.* Comparison of commercial diluents on motility, functionality and integrity of plasma membrane of bovine spermatozoa. *Rev. Bras. Cienc. Vet.*, v.25, p.57-71, 2018.

PADILHA, R.T.; MAGALHÃES-PADILHA, D.M.; CAVALCANTE, M.M. *et al.* Effect of insulin-like growth factor-I on some quality traits and fertility of cryopreserved ovine semen. *Theriogenology*, v.78, p.907-913, 2012.

PAN Y.; CUI Y.; BALOCH, A.R.; FAN, J. *et al.* Insulin like growth factor I improves yak (Bos grunniens) spermatozoa motility and the oocyte cleavage rate by modulating the expression of Bax and Bcl-2. *Theriogenology*, v.84, p.756-762, 2015.

PINTO, S.C.C.; ALMEIDA, D.S.; ALVES, M.B.R. *et al.* Does supplementation of vitamin C, reduced glutathione or their association in semen extender reduce oxidative stress in bovine frozen semen? *Arq. Brasil. Med. Vet. Zootec.*, v.72, p.9-17, 2020

SANG-MIN, S.; SUHEE, K.; JIN-GI, H. *et al.* improves mitochondrial membrane potential during hypothermic storage of canine spermatozoa. *J. Vet. Med. Sci.*, v.76, p.1065-1067, 2014.

SELVARAJU S.; REDDY, I.J.; NANDI, S. *et al.* Influence of IGF-I on buffalo (Bubalus bubalis) spermatozoa motility, membrane integrity, lipid peroxidation and fructose uptake in vitro. *Anim. Reprod. Sci.*, v.113, p.60-70, 2009. SELVARAJU, S.; KRISHNAN, B.B.; ARCHANA, S.S. *et al.* stabilizes sperm membrane proteins to reduce cryoinjury and maintain post-thaw sperm motility in buffalo (Bubalus bubalis) spermatozoa. *Cryobiology*, v.73, p.55-62, 2016.

SHOKRI, S.; EBRAHIMI, S.M.; ZIAEIPOUR, S.; NEJATBAKHSH, R. Effect of insulin on functional parameters of human cryopreserved sperms. *Cryobiology*, v.87, p.68-73, 2019.

SILVA, D.M.; ZANGERONIMO, M.G.; MURGAS, L.D.S. *et al.* Addition of IGF-I to storage-cooled boar semen and its effect on sperm quality. *Growth Horm. IGF Res.*, v.21, p.325-330, 2011.

SOUZA, F.A.; MARTINS, J.A.M.; VALE-FILHO, V.R. *et al.* Leptin and insulin in the seminal plasma of zebu bulls in peripuberty. *Rev. Bras. Zootec.*, v.41, p.923-928, 2012.

TAKEI, G.L.; MIYASHIRO, D.; MUKAI, C.; OKUNO, M. Glycolysis plays an important role in energy transfer from the base to the distal end of the flagellum in mouse sperm. *J. Exp. Biol.*, v.217, p.1876-1886, 2014.

TREULEN, F.; ARIAS, M.E.; AGUILA, L. *et al.* Cryopreservation induces mitochondrial permeability transition in a bovine sperm model. *Cryobiology*, v.83, p.65-74, 2018.

VAN-TILBURG, M.F.; SILVA, J.F.S.; DIAS, A.J.B. *et al.* Influence of insulin in the freezing of the ovine semen. *Ciênc. Anim. Bras.*, v.9, p.731-739, 2008.

WATSON, P.F. The causes of reduced fertility with cryopreserved semen. *Anim. Reprod. Sci.*, v.60-61, p.481-492, 2000.